Consequently, the FDA reclassified Mallinckrodt’s abbreviated New Drug Application (ANDA) 202608 for methylphenidate ER tablets with dosage strengths of 27 mg, 36 mg and 54 mg from AB (freely ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Ironshore Pharmaceuticals Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. and a leader in the commercialization of novel ...

Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abusive use can lead to marked tolerance and ...

ALPHARETTA, Ga., Aug. 19, 2025 /PRNewswire/ -- Alora Pharmaceuticals, LLC, the parent company of Vertical Pharmaceuticals, LLC, a leading pharmaceutical company committed to advancing access to ...

Extended-Release Is Now Chewable: First and Only Long-Acting Chewable Methylphenidate Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in patients ages 6 years old and above Monday, ...

Credit: Alora Pharmaceuticals. Relexxii (methylphenidate hydrochloride extended-release tablets) is now available for the treatment of ADHD in adults and pediatric patients. Relexxii ® ...

STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application ...

Palbociclib + Letrozole Improve Survival in Breast Cancer Pfizer announced that the FDA has approved QuilliChew ER (methylphenidate HCl extended-release) chewable tablets for the treatment of ADHD in ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg ...

Medication offers relief from 'home to homework' 25 FEBRUARY 2002 – London, UK -- A new, once-daily treatment for attention deficit hyperactivity disorder (ADHD), Concerta® XL (methylphenidate HCl), ...

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse ® (lisdexamfetamine dimesylate) compared with Concerta (methylphenidate HCl) ...

Phase 3 Adult Laboratory Classroom study confirmed that Adhansia XR provided rapid and sustained symptom relief for up to 16 hours in adults diagnosed with ADHD with a safety profile similar to ...